Yahoo Finance Video
The US House Ways and Means Committee has proposed a strategy for Medicare to cover GLP-1 weight-loss drugs like Novo Nordisk's (NVO) Wegovy and Eli Lily's (LLY) Zepbound. Yahoo Finance Health Reporter Anjalee Khemlani breaks down the details of the proposed bill ahead of Thursday's vote to amend part of the Treat and Reduce Obesity Act of 2023. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Melanie Riehl 'Follow Yahoo Finance's latest coverage on Eli Lilly and Novo Nordisk, weight-loss drugs, and the pharmaceutical industry as a whole: How Lilly is joining Novo in the crusade to circumvent Medicare's block on weight loss drugs Eli Lilly seeks to expand Zepbound use to treat sleep apnea Novo Nordisk, Eli Lilly still top 2 pharma stocks: Analyst Eli Lilly and Novo Nordisk are a 'duopoly' in GLP-1 market Why the GLP-1 impact on other industries 'will take years' Eli Lilly unveils new manufacturing plant for GLP-1 pens Novo Nordisk to invest $4.1B in NC facility for GLP-1 drugs Eli Lilly's new Alzheimer's treatment could 'lift' drug market Novo Nordisk stock rises on Wegovy approval in China